Induction of both cellular and humoral immunity following a rational prime-boost immunization regimen that incorporates recombinant ovine atadenovirus and fowlpox virus.
Recombinant fowlpox viruses (rFPV) and ovine atadenoviruses (rOAdV) are being developed as safe, nonpathogenic, prophylactic and therapeutic vaccine vectors. There is scope, however, to improve the limited immune responses elicited by each of these vaccine vectors. Using previously determined and optimized routes of administration and viral doses, we characterized the primary adaptive immune responses elicited by recombinant variants of each virus. We demonstrate the contrasting nature of the response elicited by each recombinant virus. Whereas rFPV generates predominately cell-mediated immunity to our nominal target antigen, ovalbumin (OVA), rOAdV drives strong humoral responses. By defining the time taken to achieve maximal cytotoxic T cell responses and by studying the different patterns and kinetics of major histocompatibility complex class I-restricted OVA antigen expression postimmunization, we proposed a heterologous prime-boost regimen of immunization with rOAdV followed by rFPV. The subsequent experimental results showed that this approach produced robust cell-mediated and humoral immune responses against OVA that, importantly, were accompanied by weak anti-viral vector antibody responses. These results, therefore, represent a novel and potentially clinically applicable way to achieve broadly based and effective immunity to the antigens encoded by vectored vaccines.
Fraser
Cara K
CK
Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, SA 5000, Australia.
Diener
Kerrilyn R
KR
Lousberg
Erin L
EL
Both
Gerald W
GW
Ward
Larry
L
Brown
Michael P
MP
Hayball
John D
JD
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood* / Q000276:immunology; D046808:Atadenovirus / Q000235:genetics*; D004337:Drug Carriers; D005587:Fowlpox virus / Q000235:genetics*; D005822:Genetic Vectors; D007117:Immunization, Secondary / Q000379:methods*; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000235:genetics / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014611:Vaccination / Q000379:methods*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D004337:Drug Carriers; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D010047:Ovalbumin
J Virol. 2010 Jul;84(13):6549-63
20410285
Gene Ther. 1996 May;3(5):412-20
9156802
J Immunol. 2002 Oct 15;169(8):4222-9
12370352
Clin Cancer Res. 2008 May 15;14(10):3060-9
18483372
J Virol. 1999 Aug;73(8):6930-6
10400791
J Immunol. 2001 May 1;166(9):5327-30
11313367
Cancer Immunol Immunother. 2010 May;59(5):663-74
19890632
Virology. 1997 Dec 8;239(1):226-37
9426462
J Virol. 2002 Nov;76(21):10882-93
12368331
Vaccine. 2004 Jul 29;22(21-22):2717-21
15246602
Methods Mol Med. 2007;130:69-90
17401165
Appl Microbiol Biotechnol. 2007 Oct;76(5):1131-6
17581748
Clin Cancer Res. 2003 Aug 1;9(8):2973-80
12912944
J Virol. 2005 May;79(10):6516-22
15858035
Clin Vaccine Immunol. 2008 Apr;15(4):691-6
18272665
J Virol. 2003 Nov;77(22):11941-51
14581531
J Virol. 2010 Jun;84(12):5898-908
20375158
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11349-53
8876138
Gene Ther. 1996 Feb;3(2):137-44
8867861
Science. 2007 Jan 5;315(5808):107-11
17204652
Hum Vaccin. 2007 Nov-Dec;3(6):260-7
18340117
Immunity. 1994 Aug;1(5):433-42
7533647
J Exp Med. 2002 Sep 16;196(6):817-27
12235214
Expert Rev Vaccines. 2006 Aug;5(4):565-77
16989636
Vet Microbiol. 1994 Aug 1;41(3):281-91
7975153
J Exp Med. 2000 Dec 18;192(12):1685-96
11120766
Vaccine. 1988 Dec;6(6):466-8
2854335
Vaccine. 2008 Jul 4;26(29-30):3566-73
18541346
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1401-5
7877990
Vaccine. 2009 Dec 11;28(2):474-83
19853074
N Engl J Med. 2009 Dec 3;361(23):2209-20
19843557
Immunol Cell Biol. 2000 Apr;78(2):110-7
10762410
Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10729-34
16807294
Immunity. 2007 Jun;26(6):827-41
17555991
Lancet. 2008 Nov 29;372(9653):1881-1893
19012954
Biotechniques. 2004 Jul;37(1):104-6, 108-11
15283207
J Exp Med. 2008 Jan 21;205(1):7-12
18195078
J Exp Med. 2002 Oct 21;196(8):1079-90
12391019
J Immunother. 2009 Oct;32(8):870-4
19752747
Curr Opin Biotechnol. 2007 Dec;18(6):546-56
18063357
Arch Virol. 1998;143(4):829-37
9638153
Science. 2003 Sep 26;301(5641):1925-8
14512632
Vaccine. 2008 Dec 9;26(52):6883-93
18940219
Clin Cancer Res. 2008 Aug 15;14(16):5284-91
18698048
Blood. 2007 Sep 15;110(6):1916-23
17510320
Exp Hematol. 2008 Jan;36(1):51-60
17949888
AIDS. 2010 Aug 24;24(13):1983-90
20634666
Curr Opin Mol Ther. 2009 Aug;11(4):421-32
19649987
J Exp Med. 2002 May 20;195(10):1289-302
12021309
J Immunol Methods. 1994 May 2;171(1):131-7
8176234
J Virol. 2004 Oct;78(20):11434-8
15452269
Immunol Rev. 2010 Mar;234(1):142-62
20193017